Sol-Gel Technologies to Present at Upcoming Jefferies Healthcare Conference and Raymond James Human Health Innovation Conference

Rhea-AI Summary

Sol-Gel Technologies, a clinical-stage dermatology firm, will present a company overview at two upcoming virtual investor conferences. The first is the Jefferies Healthcare Conference, scheduled for June 1, 2021, where CEO Dr. Alon Seri-Levy will speak at 8:30 am EDT. The second is the Raymond James Human Health Innovation Conference on June 22, 2021, at 10:00 am EDT. The company focuses on developing topical treatments for skin diseases, with NDA submissions for two products pending FDA review. Recordings of the presentations will be available on their website.

NESS ZIONA, Israel, May 27, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), (“Sol-Gel”), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced that the Company will present a Company overview and business update at the following upcoming virtual investor conferences:

Jefferies Healthcare Conference (June 1 – 4, 2021)
Speaker:	Dr. Alon Seri-Levy, Chief Executive Officer
Date:	Tuesday, June 1, 2021
Time:	8:30 – 8:55 am EDT
Raymond James Human Health Innovation Conference
(June 21 – 23, 2021)
Speaker:	Dr. Alon Seri-Levy, Chief Executive Officer
Date:	Tuesday, June 22, 2021
Time:	10:00 – 10:30 am EDT

A recording of the webcast of each presentation will be available in the Investors/Events & Presentations section of the Company’s website at www.sol-gel.com.

About Sol-Gel Technologies

Sol-Gel is a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Sol-Gel leverages its proprietary microencapsulation technology platform for the development of TWYNEO^®, under investigation for the treatment of acne vulgaris with an NDA filed with the FDA and a PDUFA goal date set for August 1, 2021; and EPSOLAY^®, under investigation for the treatment of inflammatory lesions of rosacea with an NDA filed with the FDA and a PDUFA goal date set for April 26, 2021. Action on the NDA for EPSOLAY has not yet been taken due to the inability of the FDA to conduct a pre-approval inspection of the production site of EPSOLAY as a result of COVID-19 travel restrictions. The Company’s pipeline also includes SGT-210, an early-stage topical epidermal growth factor receptor inhibitor, erlotinib, under investigation for the treatment of palmoplantar keratoderma, and preclinical assets tapinarof and roflumilast. For additional information, please visit www.sol-gel.com.

For further information, please contact:

Sol-Gel Technologies

Gilad Mamlok Chief Financial Officer +972-8-9313433

Investor relations Irina Koffler LifeSci Advisors +1-917-734-7387 ikoffler@lifesciadvisors.com

FAQ

What events will Sol-Gel Technologies present at in June 2021?

Sol-Gel Technologies will present at the Jefferies Healthcare Conference from June 1-4 and the Raymond James Human Health Innovation Conference from June 21-23, 2021.

Who will speak for Sol-Gel Technologies at the Jefferies Healthcare Conference?

Dr. Alon Seri-Levy, the CEO of Sol-Gel Technologies, will present at the Jefferies Healthcare Conference.

What is the time for Sol-Gel's presentation at the Jefferies Healthcare Conference?

The presentation is scheduled for June 1, 2021, at 8:30 am EDT.

When will Sol-Gel Technologies present at the Raymond James Human Health Innovation Conference?

Sol-Gel Technologies will present on June 22, 2021, at 10:00 am EDT.

What are the NDA submission dates for Sol-Gel's products?

The NDA for EPSOLAY is pending action due to COVID-19 restrictions, while TWYNEO has a PDUFA goal date set for August 1, 2021.